The mutual fund has acquired around 2.64 lakh shares, representing 1.15% of total shareholding, of the company

As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium

This is a momentous opportunity as it will allow Sanofi to unlock and maximise its business potential in both pharmaceuticals and consumer healthcare, with the right assets, structure, and strategy